<DOC>
	<DOC>NCT00599339</DOC>
	<brief_summary>This study will be conducted in an observational multiple-cohort design aimed at acquiring clinical, treatment, health status, and economic data. Patients with Parkinson's disease (PD) will be enrolled.</brief_summary>
	<brief_title>Transdermal Rotigotine User Surveillance Study</brief_title>
	<detailed_description>All patients attending the physician and fulfilling the eligibility criteria are included.</detailed_description>
	<mesh_term>Parkinson Disease</mesh_term>
	<mesh_term>N 0437</mesh_term>
	<mesh_term>Dopamine Agonists</mesh_term>
	<mesh_term>Dopamine</mesh_term>
	<mesh_term>Dopamine Agents</mesh_term>
	<mesh_term>Levodopa</mesh_term>
	<criteria>Patients with idiopathic earlystage Parkinson's Disease requiring dopaminergic monotherapy (rotigotine, other dopamine agonists or levodopa) at study onset Patients with advancedstage Parkinson's Disease requiring dopaminergic therapy with levodopa in combination with rotigotine or other dopamine agonists at study onset Patients who are unable to comply with study requirements</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2015</verification_date>
	<keyword>Rotigotine</keyword>
	<keyword>Neupro</keyword>
</DOC>